In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance requires longer studies with more participants. Given that PAH is a rare disease, finding large numbers of participants is a problem. Innovative trial designs offer new options while still providing good data.
top of page
Recent Posts
The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial...
Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new...
Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size...
bottom of page
Comments